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Background: Salvinorin A (SA), the main active component of Salvia Divinorum, is a non-nitrogenous kappa opioid
receptor (KOR) agonist. It has been shown to reduce acute pain and to exert potent antinflammatory effects. This
study assesses the effects and the mode of action of SA on formalin-induced persistent pain in mice. Specifically,
the SA effects on long-term behavioural dysfuctions and changes in neuronal activity occurring at spinal level, after
single peripheral formalin injection, have been investigated. Moreover, the involvement of microglial and glial cells
in formalin-induced chronic pain condition and in SA-mediated effects has been evaluated.
Results: Formalin induced a significant decrease of mechanical withdrawal threshold at the injected and
contralateral paw as well as an increase in the duration and frequency, and a rapid decrease in the onset of evoked
activity of the nociceptive neurons 7 days after formalin injection. SA daily treatment significantly reduced
mechanical allodynia in KOR and cannabinoid receptor 1 (CB1R) sensitive manner. SA treatment also normalized the
spinal evoked activity. SA significantly reduced the formalin-mediated microglia and astrocytes activation and
modulated pro and anti-inflammatory mediators in the spinal cord.
Conclusion: SA is effective in reducing formalin-induced mechanical allodynia and spinal neuronal hyperactivity.
Our findings suggest that SA reduces glial activation and contributes in the establishment of dysfunctions
associated with chronic pain with mechanisms involving KOR and CB1R. SA may provide a new lead compound for
developing anti-allodynic agents via KOR and CB1R activation.
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Abnormal pain responses such as mechanical allodynia
and thermal hyperalgesia are commonly associated with
chronic pain states. Following peripheral or central ner-
vous system (CNS) insults, neuron sensitization occurs
leading to pain transmission facilitation [1,2]. Spinal glia
(microglia and astrocytes) strongly contribute to the devel-
opment and maintenance of chronic pain [3,4]. In patho-
logical condition, microglia cells undergo to activation
resulting in morphological changes and in the release of* Correspondence: francesca-guida@libero.it
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reproduction in any medium, provided the orseveral neuromodulators, contributing to the mechanisms
of central sensitization [5-7]. Once activated, they recruit
other microglia and extend the inflammation by activating
astrocytes, which are required for the maintenance of the
pain state [8]. The involvement of spinal glial and micro-
glial cells in pain regulation is supported by the use of spe-
cific metabolic inhibitors [9,10] and their activation has
been described in several animal pain models, including
peripheral nerve injury [11-13] and intra-plantar zymosan
or formalin administration [14-16]. Formalin injection into
the hind-paw of rodents is a pain model widely used to in-
vestigate the mechanisms of persistent nociception. It pro-
duces a severe and immediate peripheral inflammation
and nocifensive behaviour, but it is also associated withtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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morphological changes lasting at least 14 days [17]. The
opioid system is strongly implicated in pain control
mechanisms [18-21]. Opioid μ, κ and δ receptors (MOR,
KOR, DOR) activation at peripheral and spinal level
induces intense analgesia by inhibition of excitatory trans-
mission or via stimulation of descending antinociceptive
pathway [22]. SA, a potent non-opioid selective KOR
agonist, is the main active component of the plant Salvia
Divinorum [23,24]. It exerts intense hallucinogenic effects,
such as to lead to a kind of “out of the body” experience
comparable to lysergic acid diethylamide effect [25]. SA
has been demonstrated to be effective in some acute pain
models [26-29] and we have recently demonstrated that it
has an ultrapotent anti-inflammatory effect in LPS- and
carrageenan-induced paw oedema [30].
In this study we have evaluated the effects of SA on
formalin-induced pain symptoms. We have evaluated
the possible anti-allodynic effect of daily SA treatment
up to 7 days after subcutaneous formalin injection in
mice. Moreover, we performed electrophysiological
recordings of nociceptive neurons (NS), in order to in-
vestigate a possible neuronal activity changes induced by
SA in formalin-injected mice. Finally, the involvement of
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Figure 1 Effect of SA (0.5, 1 and 2 mg/kg i.p.) repeated treatment on
contralateral (B, D) hind paw 3 and 7 days after formalin injection in
nor-BNI (20 mg/kg i.p.), AM251 (1 mg/kg i.p.) or AM630 (1 mg/kg i.p.) (C, D
thresholds in grams. # indicate significant differences vs veh/saline-treated
injected mice and ° indicate significant differences vs SA/formalin injected
ANOVA followed by Student-Newman Keuls).inflammatory mediators in the SA-mediated effects at
the spinal cord level was also investigated.
Results
SA repeated treatment reduces formalin-induced
mechanical allodynia in KOR and CB1R sensitive manner
Formalin injection on the dorsal surface of hind-paw
induced an increase in paw volume and spontaneous
pain behaviour. Accordingly with previous studies
[14,17] we found a significant decrease of mechanical
threshold in the injected and contralateral paw 3 and
7 days after formalin administration as compared to the
saline-injected mice (Figure 1A and B). The subcutane-
ous injection of saline into the paw or intraperitoneal ve-
hicle administration did not change the pain response as
compare with naive mice (not shown). We found that
SA (2 mg/kg, i.p.) daily treatment significantly reduced
the formalin-induced mechanical allodynia at 3 and
7 days in both ipsi and contralateral paws. Lower doses
of SA (0.5 and 1 mg/kg) did not exert any changes
(Figure 1A and B). The SA anti-allodynic effect was pre-
vented by the concurrent treatment with nor-BNI
(20 mg/kg, i.p.), a KOR selective antagonist, and with
AM251 (1 mg/kg i.p.), a CB1 receptor selective antagon-
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mechanical withdrawal threshold of the ipsi- (A, C) and
mouse. SA (2 mg/kg i.p.) was also administered in combination with
). Data were expressed as mean± SEM of mechanical withdrawal
mice, * indicate significant differences vs vehicle treatment in formalin
mice. P values <0.05 were considered statistically significant (one-way
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We also compared the effects of SA to those of U-
50488, a well-established selective synthetic KOR
agonist. Similarly to SA, U-50488 (2 mg/kg, i.p.)
had anti-allodynic properties which were prevented
by KOR and CB1R selective antagonists, but not by
a CB2R selective antagonist (Figure 2A and B).
Moreover, we observed that chronic treatment with
AM251 or nor-BNI, but not AM630, slightly increased
the nociceptive response induced by formalin injection,
even if the effect was not significant (not shown).
The dose of SA used (2 mg/kg i. p.) did not change
the normal behaviours, neither induced sedation or
motor impairment in saline or formalin-treated mice.
Effect of SA on the NS neurons activity in
formalin-treated mice
The in vivo electrophysiological experiments were per-
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Figure 2 Effects of U-50488 (2 mg/kg i.p.) repeated treatment
alone or in combination with nor-BNI (20 mg/kg i.p.), AM251
(1 mg/kg i.p.) or AM630 (mg/kg i.p.) on mechanical withdrawal
threshold of the the ipsi- (A) and contralateral (B) hind-paw 3
and 7 days after formalin injection in mouse. Data were
expressed as mean ± S.E.M of mechanical withdrawal thresholds in
grams. # indicate significant differences vs veh/saline treated mice,
* indicate significant differences vs vehicle treatment in formalin
injected mice and ° indicate significant differences vs U-50488
/formalin injected mice. P values <0.05 were considered statistically
significant (one-way ANOVA followed by Student-Newman Keuls).neuron activity in formalin-induced inflammatory pain
conditions with or without SA. The results are based on
NS neurons (one cell recorded from each animal per
treatment) at a depth of 0.7-1 mm from the surface of
the spinal cord. This cell population was characterized
by a mean rate of spontaneous firing of 0.015 ± 0.002
spikes/sec and only cells showing this pattern of basal
firing were chosen for the experiment. Saline or formalin
paw-injection did not change the spontaneous activity of
NS neurons as shown in Figures 3, 4 and 5, while we
observed significant changes in the evoked neuronal ac-
tivity, measured by analyzing different parameters as
onset, duration and frequency, 7 days after the formalin
injection. We observed that formalin did not modify
neuronal activity 3 days post-injection. SA application
locally to the spinal cord, however, increased the onset
and reduced the frequency of the evoked activity as
compared to both mice receiving intra-paw formalin and
vehicle and mice receiving intra-paw saline and vehicle
(Figure 3 A and C). We found a significant increase in
duration and frequency and a decrease in the onset of
the evoked activity (39 ± 5 s, 19.6 ± 1.3 spikes/s,
172 ± 9 ms, respectively; P <0.05) 7 days after formalin
paw-injection as compared to mice receiving intra-paw
saline (Figure 4 A, B and C). Topical spinal cord applica-
tion of SA (50 μg/10 μl) transiently reversed the
formalin-induced changes in duration, frequency and
the onset of the evoked cell activity (3 ± 0.3 s, 6.2 ± 0.3
spikes/s, 550 ±2 5 ms P <0.05). Repeated SA treatment,
at the dose effective in alleviating mechanical allodynia
(2 mg/kg, i.p.), completely normalized the induced-
formalin changes 7 days after formalin injection. In
particular, SA reduced the duration and frequency,
while increased the onset of the evoked activity
(1.9 ± 0.9 s, 2.4 ±0.4 spikes/s, 550 ± 21 ms respectively;
P <0.05) of NS neurons in formalin-injected mice as com-
pared to vehicle (0.05% DMSO in aCSF), while no signifi-
cant changes were found in 3 days SA-treated mice
(Figure 5 A, B and C). Representative ratemater records
show the activity of a single NS neuron before and after a
single vehicle or SA spinal cord topical application (Fig-
ure 3 D and E and Figure 4 D, E and F) and repeated treat-
ment with vehicle or SA in mice receiving saline or
formalin into the hind-paw (Figure 5 D, E and F).Changes in expression of cannabinoid and opioid
receptors after formalin injection
Western blot analysis revealed a significant up-regulation
of CB1 receptor (but not CB2 receptor or KOR) protein
levels 3 days after formalin administration as compared
with saline-treated mice (Figure 6). No significant
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Figure 3 Effects of spinal cord application of vehicle (0.05% DMSO in aCSF) or SA (50 μg/10 μl) on the onset (A), duration (B) and
evoked frequency (C) of NS neurons in mice which received saline or formalin injection into the hind-paw. Vehicle or SA were
administered 3 days after saline or formalin as indicated by black arrows. Each point represents the mean ± S.E.M of 6–8 neurons of different
treated groups of mice. # indicates significant differences vs veh/form. P values <0.05 were considered statistically significant (one-way ANOVA
followed by Student-Newman Keuls). Representative ratemeters (D and E) show the responses to a noxious stimulation (von Frey filaments 97.8
mN/2 sec) of a single NS neuron both before and after vehicle or SA spinal application. Grey arrow indicates vehicle or SA application, while
black triangle indicate the noxious stimulation on the mouse hind-paw.
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tion at spinal cord level Immunohistochemical evaluations
were performed in order to determine the occurrence of
spinal microglia and astrocytes activation following intra-
paw formalin injection. Morphological analysis of Iba-1
positive cells, accordingly to the criteria described by
Hains and Waxman [31], revealed that formalin increased
the number of activated microglial cells in the ipsilateral
dorsal horn (L4–L6) 3 and 7 days post-injection as com-
pared to saline-treated mice (Figure 7A, B and C). SA
repeated treatment (2 mg/kg, i.p.) significantly reduced
the number of morphologically activated microglia cells
induced by formalin injection (Figure 7D and E). In
addition, we observed that formalin increased the number
of hypertrophic GFAP-labelled astrocytes 3 and even more7 days post-injection as compared to saline-injected mice
(Figure 8C). SA repeated treatment (2 mg/kg, i.p.) strongly
abolished the formalin-induced reactive gliosis 7 days
post-formalin injection as shown in Figure 8E. In a sep-
arate set of experiments, we have evaluated the involve-
ment of CB1R and KOR in the SA-mediated effects on
spinal microglia and astrocytes activation. We decided
to perform these evaluations 7 days post formalin injec-
tion, which represent the peak of maximum cells activa-
tion. In particular, we found that AM251 treatment
abolished the SA effect on the activation of both micro-
glia and astrocytes, while a slight reduction of SA effects
was found in nor-BNI-treated mice only in astrocytes
activation (Additional file 1: Figure S1 and Additional






































































































Figure 4 Effects of spinal cord application of vehicle (0.05% DMSO in aCSF) or SA (50 μg/10 μl) on the onset (A), duration (B) and
evoked frequency (C) of NS neurons in mice which received saline or formalin injection into the hind-paw. Vehicle or SA were
administered 7 days after saline or formalin peripheral injection as indicated by black arrows. Each point represents the mean ± S.E.M of 6–8
neurons of different treated groups of mice. * indicates statistically significant differences vs veh/saline and # indicates statistically significant
differences vs veh/form. P values <0.05 were considered statistically significant (one-way ANOVA followed by Student-Newman Keuls).
Representative ratemeters (D, E and F) show the responses to a noxious stimulation (von Frey filaments 97.8 mN/2 sec) of a single NS neuron
both before and after vehicle or SA (50 μg/10 μl) spinal application. Grey arrow indicates vehicle or SA application, while black triangle indicate
the noxious stimulation on the mouse hind-paw.
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formalin-injected mice
Formalin injection caused hyper-expression of i-NOS, an
effect which was statistically significant 3, but not 7, days
after its injection (Figure 9A). The increase in iNOS ex-
pression, which was found over-expressed in Iba-1 la-
belled microglial cells (Figure 9B), was normalised by SA
(Figure 9A).
Similarly, IL-10 levels were significantly down-
regulated 3, but not 7, days after formalin injection in the
spinal cord (Figure 9C). The 3-days treatment with SA
normalized IL-10 levels (Figure 9C). Moreover, by using
an immunohistochemical approach, we were able to de-
tect IL-10 in GFAP labelled astrocytes only in the spinal
cord of SA treated mice (Figure 9D). Very weak stainingwas detectable in the saline or formalin-injected mice
(not shown).
Discussion
The main finding of this study is the anti-allodynic effect
of SA, the main compound of Salvia Divinorum, in a
formalin-induced chronic pain model in mouse. We
have here coupled behavioural pharmacology with
in vivo electrophysiology in order to: 1) clarify the long-
lasting behavioural responses and NS neuronal activity
induced by a single formalin injection 2) investigate the
contribute of KOR/CB1 receptor manipulation in
formalin-induced pain condition. In particular, we have
shown that SA repeated treatment, reduces mechani-
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Figure 5 Effects of vehicle (0.05% DMSO in aCSF) or SA (2 mg/kg, i.p.) repeated treatment on the onset (A), duration (B) and evoked
frequency (C) of NS neurons 3 or 7 days after the injection of saline or formalin into the hind-paws. Each point represents the
mean ± S.E.M of 6–8 neurons of different treated groups of mice. * indicates statistically significant differences vs veh/saline and # indicates
statistically significant differences versus veh/form. P values <0.05 were considered statistically significant (one-way ANOVA followed by
Student-Newman Keuls). Ratemeters show the responses to a noxious stimulation (von Frey filaments 97.8 mN/2 sec) of a single representative
NS neuron in mice receiving veh/saline (D), veh/form (E) or SA/form (F). Black triangles indicate the noxious stimulation on mouse hind-paw.
Scale bar indicates 5 min intervals for ratemeter records.
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into the hind-paw of rodents has been considered
mainly a model of persistent inflammatory pain, which
induces a characteristic nocifensive biphasic response,
oedema and inflammation [32]. We have previously
demonstrated that a single administration of SA par-
tially reduced the first phase of formalin-induced noci-
ceptive behaviour, which is caused by direct activation
of nociceptive sensory afferents, and it completely abol-
ished the second one [30] which is due to the release of
inflammatory mediators and it is also associated with
central sensitization [33-35]. However, peripheral for-
malin injection also exerts long-term nerve injury
[15,17,36,37]. Accordingly, we have shown that formalin
leads to tactile allodynia ipsilaterally to the injection
side spreading also to the contralateral hind-paw. SA
was effective in reducing the formalin-induced ipsi- and
contralateral allodynia up to 7 day treatment. Moreover,
we found that SA effects were prevented by KOR andCB1R selective antagonists. Indeed, the involvement of
CB1 receptor in SA-mediated effects has been already
shown in other inflammatory animal models [30,38]
and also in emotional behaviour studies in rodents [39].
How SA can reduce pain transmission by modulating
CB receptors is presently unclear. SA shows very low or
no affinity for CB1 and CB2 receptors, respectively, and
it seems to be unable to modulate significantly endo-
cannabinoid levels [38,40]. The finding that the effect of
U-50488, the synthetic KOR agonist, was counteracted
by nor-BNI and AM251 similarly to SA, suggests a pos-
sible functional KOR-CB1R interaction rather than an
exclusive effect of the drug. Several findings have sug-
gested that a functional cross-talk between cannabinoid
and opioid systems exists [41-43], even if the mechan-
isms of such interaction are not still clear. A direct re-
ceptor–receptor interaction, such as heteromerization,
as already suggested by Rios et al., [44] for CB1R and









































































































Figure 6 Effect of vehicle or SA on CB1, CB2 and KOR expression in the dorsal horn of formalin-injected mice (A-C). Data are expressed
as mean ± S.E.M of 3 mice per group. * indicates statistically significant differences vs veh/saline 3 day after formalin (P <0.05, t-test).
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interaction has been described with particular emphasis
on the pivotal role of opioid receptors and peptides in
cannabinoid-mediated analgesia [41,43] and importantly,
such a functional interaction between the two systems
seem to be altered during chronic pain [45]. In our
model, we found a significantly increase of spinal CB1
receptor expression, while no changes have been
detected for CB2R or KOR. The involvement of the
CB2R, which is known to play an important role in
chronic inflammatory process and also in reducing pain
behaviour associated with neuropathic pain [13,46-48]
has been also object of this study. The co-administration
of SA with AM630, the selective CB2 receptor antag-
onist, ruled out the contribute of this receptor in
SA-mediated effects.
Inflammation, tissue damage or nervous system injury
result in the activation of immune and inflammatory
cells, leading to consequent production of several media-
tors able to increase pain hypersensitivity. By using
immunohistochemical approaches, we have found that
formalin induces an increase of Iba-1 staining, a marker
of microglia cells, in the dorsal horn of lumbar spinal
cord ipsilaterally to the injection, as previously demon-
strated [15,49]. In this study we also have observed an
increase of hypertrophic GFAP positive cells 7 days
post-injection in the same area. Astrocytes and microglia
cells showed a typical morphological shape correspond-
ing to the activated phenotype. The effectiveness of SA
in alleviating mechanical allodynia matched with areduction of the activated cells number and with the
modulation of IL-10 and iNOS, two different markers
involved in the inflammatory processes. In this study we
found that, at time point evaluated, the IL-10 protein
level was increased by SA treatment in terms of intracel-
lular production compared to saline or formalin treated
animals, as revealed by immunohistochemestry, while it
was normalized in the released form, as revealed by
ELISA. These data suggest that the mechanisms leading
to the long-term nocifensive behaviour induced by for-
malin are correlated with a reorganization of the spinal
cellular populations in which microglia and astrocytes
activation play a significant role. In this context, the ef-
fectiveness of SA in reducing the activation of astrocytes
and even more of microglia seems to be mainly
mediated by CB1R rather than KOR. Indeed, we found
that chronic treatment with AM251, but not nor-BNI,
(see Additional file 1: Figure S1 and Additional file 2:
Figure S2) reverted the effect of SA in reducing micro-
glial activation. These data are consistent with the evi-
dence showing that cannabinoids are more effective than
opioids in alleviating neuropathic pain [50].
Importantly - and consistently with the behavioural
data - electrophysiological experiments revealed that SA
caused a strongly reduction of evoked activity of NS
neurons in formalin-injected mice, suggesting that KOR/
CB1R activation plays an important role in the transmis-
sion of noxious signals to the spinal cord under patho-
logical conditions. Indeed, our findings are the first one
showing the long-lasting effects of formalin injection on
veh/saline veh/form 3d veh/form 7d
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Figure 7 Effect of vehicle or SA repeated treatment (2 mg/kg, i.p.) on spinal microglial cells in mice receiving saline or formalin into
the hind-paws. Iba-1 immunoreactivity (Iba-1-ir) is shown in the ipsilateral dorsal horn 3 (B and D) and 7 (C and E) days after saline or formalin
(A). “F” and ‘G” represent examples of resting and activated microglia cell morphology, respectively. Quantitative analysis of percentage of
activated microglial cells on the total cell number in L4-L6 spinal cord sections is shown in “H”. Data are expressed as mean ± S.E.M of 3 mice per
group. * and • indicate statistically significant differences vs veh/saline. † indicates statistically significant differences vs veh/form 3 day after
formalin and ° indicates statistically significant differences vs veh/form 7 days after formalin (P <0.05, one-way ANOVA, Tukey post hoc).
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tion and the increased responsiveness to mechanical
noxious stimuli of NS neurons found 7 days after for-
malin, suggest that a single peripheral formalin injec-
tion, beyond motor dysfunctions, induces a central
sensitisation, similarly to a neuropathic pain condition
induced by nerve injury. The finding that 7 days are
needed to modulate spinal neuronal activity seems to
be in contrast with allodynia development and with the
lack of changes in spinal pro-inflammatory mediator
level, observed already 3 days post-injection. However,
this may be due to the formalin-induced intense inflam-
mation with an immediate production of prostaglandins
and accumulation of neutrophils and infiltrating mono-
nuclear cells which could be alone responsible for the
induction of allodynia. Indeed, a range of peripheral in-
flammatory stimuli, such as the peripheral injection of
carageenan, mustard oil and complete Freund’s adju-
vant, have been shown to induce a robust allodynia and
hyperalgesia in adult animals [51,52]. In our model, theinitial microglial activation and/or the release of pro-
inflammatory cytokines appears to be unable to
sensitize dorsal horn sensory neurons. It would be rea-
sonable to hypothesize that microglia and astrocytes
can participate together in neuronal sensitization, not
only by releasing cytokines and various mediators, but
also more directly via release of glutamate and/or by
evoked-changes in synaptic ion currents [6]. The evi-
dence of the crucial role of astrocytes in the mainten-
ance of mechanical allodynia in chronic pain and our
finding that astroglial activation does not occur until to
the 7th day after formalin injection, supports their in-
volvement in the establishment of central sensitization.
Moreover, some brain areas of the endogenous antinoci-
ceptive pathway, i.e. periaqueductal gray (PAG)-rostral
ventromedial medulla (RVM) axis, could be activated in
pathophysiological conditions associated with persistent
pain, so reducing neuronal sensitization at spinal level.
In fact, previous findings showing an increased endo-
cannabinoid release within the dorsal and lateral PAG
hypertrophic
veh/saline veh/form 3d veh/form 7d
form 3d + SA form 7d + SA
resting
%
3 days 7 days












Figure 8 Effect of SA repeated treatment (2 mg/kg, i.p.) on spinal astrocytes in mice receiving saline or formalin into the hind-paws.
GFAP immunoreactivity (GFAP-ir) is shown in the ipsilateral dorsal horn 3 (B and C) and 7 (D and E) days post-saline (A) or formalin. “F” and ‘G”
represent examples of resting and activated astrocytes morphology, respectively. Quantitative analysis of percentage of hypertrophic astrocytes
on the total cell number in L4-L6 spinal cord sections is shown in “H”. Data are expressed as mean ± S.E.M of 3 mice. * and • indicate statistically
significant differences vs veh/saline. ° indicates statistically significant differences vs veh/form 7 days after formalin injection, one-way ANOVA,
Tukey post hoc).
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sible activation of CB1 receptors in such areas in in-
flammatory conditions, which could be responsible for
the inhibition of the spinal NS neurons over-excitability.
Conclusion
In conclusion, this findings show that SA is effective in
reducing formalin-induced mechanical allodynia with a
mechanism involving KOR and CB1. Moreover, SA
reduced spinal neuron hyperexcitability and the glial
contribute in the establishment of some critical pheno-
typical changes in the spinal cord associated with
chronic pain development. SA could provide a novel




Male ICR (CD-1) mice (30–35 g) were housed 3 per
cage under controlled illumination (12:12 h light:dark
cycle; light on 06.00 h) and environmental conditions(room temperature 20-22°C, humidity 55-60%) for at
least 1 week before the commencement of experi-
ments. Mouse chow and tap water were available ad
libitum. The experimental procedures were approved
by the Animal Ethics Committee of the Second Uni-
versity of Naples. Animal care was in compliance with
the IASP and European Community (E.C. L358/1 18/
12/86) guidelines on the use and protection of animals
in experimental research. All efforts were made to
minimize animal suffering and to reduce the number
of animals used. Groups of 6–8 mice for behavioral
and electrophysiological experiments and groups of 3
mice for ex vivo studies received subcutaneous injec-
tion of 30 μl of saline (0.9% NaCl) or formalin (1.25%)
into the dorsal surface of the right hind paw. Repeated
treatments (i.p.) were performed ones a day and all
the evaluations have been carried out before each in-
jection. The doses used were in accord with our previ-
ous data [30].
For behavioral test, molecular evaluations and immu-






Figure 9 Effect of SA (2 mg/kg, ip) on i-NOS expression (A) and IL-10 levels (C) in mice receiving saline or formalin into the hind paw
(3 and 7 days). Data are expressed as mean ± S.E.M (n = 3) in “A” * indicates significant differences vs veh/saline and # indicates significant
differences vs veh/form (P <0.05, t-test). In “C” ** indicates significant differences vs veh/saline and ° indicates statistically significant differences vs
veh/form (P <0.05, t-test). “B” represents iNOS expression up-regulation in the ipsilateral dorsal horn. Double labeling shows the iNOS expression
in microglia. “D” represents IL-10 levels up-regulation in the ipsilateral dorsal horn. Double labeling shows the IL-10 level in astrocytes.
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follows:
1) vehicle (0.5% DMSO in 0.9% NaCl, i.p.) or SA (0.5, 1
and 2 mg/kg, i.p.).
2) SA (2 mg/kg i.p.), U-50488 (2 mg/kg i.p.) alone or in
combination with nor-BNI (20 mg/kg, i.p.), AM251
(1 mg/kg, i.p.) and AM630 (1 mg/kg, i.p.).
For the electrophysiological recordings groups of 6–8
mice received subcutaneous injection of saline or forma-
lin into the dorsal surface of the right hind paw and
were treated as follows:
1) spinal topic application of vehicle (DMSO/aCSF,
0.05%, v/v) or SA (50 μg/10 μl).
2) repeated treatment (3 or 7 days) with vehicle (0.5%
DMSO in 0.9% NaCl, i.p.) or SA (2 mg/kg i.p.).
Nociceptive behavior
Mechanical allodynia was measured by using the Dy-
namic Plantar Aesthesiometer (Ugo Basile, Varese, Italy).
Mice were allowed to move freely in one of the twocompartments of the enclosure positioned on the metal
grid surface. A mechanical stimulus was delivered to the
plantar surface of the hind-paw of the mouse through
the metal grid by an automated steel filament exerting
an increasing force of 0–30 grams in 10 seconds. The
force inducing paw withdrawal was recorded to the
nearest 0.1 g. Nociceptive responses for mechanical sen-
sitivity (mechanical withdrawal threshold) were mea-
sured in grams. Baseline thresholds were determined
6 days before starting with the treatments. The observer
was blind to the treatments.
Electrophysiological recordings
On the day of electrophysiological recording experi-
ments, mice were initially anaesthetized with sodium
pentobarbital (50 mg/kg, i.p.). After tracheal cannulation,
a catheter was placed into the right external jugular vein,
to allow continuous infusion of propofol (5–10 mg/kg/h,
i.v.) and spinal cord segments L4-L6 were exposed by
laminectomy, medially near the dorsal root entry zone
up to a depth of 1000 μm. An elliptic rubber ring (about
3 × 5 mm) was tightly sealed with silicone gel onto the
surface of the cord. This ring formed a trough with
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topical spinal drug application and to gain access to
spinal neurons. Animals were then secured in a stereo-
taxic apparatus (David Kopf Instruments, Tujunga, CA,
USA) supported by clamps attached to the vertebral pro-
cesses on either side of the exposure site. Body
temperature was maintained at 37°C with a temperature-
controlled heating pad [54,55]. A glass-insulated tung-
sten filament electrode (3–5 MΩ) (FHC Frederick Haer
& Co., ME, USA) was used to record single unit extra-
cellular activity of dorsal horn NS neurons. NS neurons
were defined as those neurons responding only to high-
intensity (noxious) stimulation [54] for saline or
formalin-injected animals, each neuron was character-
ized by giving a mechanical stimulation to the injected
paw by von Frey filament with a bending force of 97.8
mN (noxious stimulation) for 2 s with it slightly buckled
to confirm NS response patterns. Only neurons that
specifically responded to noxious hind paw stimulation,
without responding to stimulation of the surrounding
skin/tissue, were considered for recordings. The
recorded signals were amplified and displayed on a
digital storage oscilloscope to ensure that the unit under
study was unambiguously discriminated throughout the
experiment. Signals were also fed into a window dis-
criminator, whose output was processed by an interface
CED 1401 (Cambridge Electronic Design Ltd., UK) con-
nected to a Pentium III PC. Spike2 software (CED, ver-
sion 4) was used to create peristimulus rate histograms
on-line and to store and analyze digital records of single
unit activity off-line. Configuration, shape, and height of
the recorded action potentials were monitored and
recorded continuously using a window discriminator
and Spike2 software for on-line and off-line analysis.
This study only included neurons whose spike configur-
ation remained constant and could clearly be discrimi-
nated from activity in the background throughout the
experiment, indicating that the activity from one neuron
only and from the same neuron was measured. Spon-
taneous and evoked neuronal activity was recorded in
different groups of animals after repeated vehicle or
drug administration and local vehicle or drug applica-
tion. The neuronal activity was expressed as spikes/sec
(Hz) and only one neuron was recorded in each mouse.
At the end of the experiment, each animal was killed
with a lethal dose of pentobarbital.
Spinal cord immunohistochemistry
Under pentobarbital anaesthesia (50 mg/kg, i.p.), animals
were transcardially perfused with saline solution fol-
lowed by 4% paraformaldehyde in 0.1 M phosphate buf-
fer. The lumbar spinal cord was excised, post fixed for
3 h in the perfusion fixative, cryoprotected for 72 h in
30% sucrose in 0.1 M phosphate buffer and frozen inO.C.T. embedding compound. Transverse sections (20 μm)
were cut using a cryostat and thaw-mounted onto glass
slides. Slides were incubated overnight with primary anti-
body solutions for the microglial cell marker Iba-1
(rabbit anti-ionized calcium binding adapter molecule-1;
1:1000; Wako Chemicals, Germany), GFAP (rabbit poly-
clonal anti-glial fibrillar acidic protein, 1:1000; Dako
Cytomation, Denmark) IL-10 (goat anti-interleukin 10,
1:100; Santa Cruz, USA) or iNOs (mouse anti-iNOs
BD Biosciences Pharmigen). A possible unspecific label-
ing of mouse secondary antibody has been detected by
using secondary antibody alone. Following incubation
sections were washed and incubated for 2 hrs with
secondary antibody solution. Slides were washed, cover-
slipped with Vectashield mounting medium (Vector
Laboratories, USA) and visualized under a Leica fluores-
cence microscope.
Quantitative image analysis
The number of profiles positive for Iba-1, GFAP and IL-
10 were determined within a box measuring 104 μm2 in
the lateral, central and medial areas of the dorsal horn
spinal cord sections, at both ipsilateral or contralateral
sides. Eight L5 spinal sections were assessed from each of
three animals per group, and a mean value obtained by
combining values from lateral, central and medial areas
of dorsal horn. To avoid cell over-counting, only DAPI-
counterstained cells were considered as positive profiles.
Resting and activated microglia were classified based on
the following criteria: resting microglia displayed small
somata bearing long, thin and ramified processes
whereas morphologically activated microglia exhibited
marked cellular hypertrophy and retraction of processes
such that the process length was less than the diameter
of the soma size. Cells were sampled only if the nucleus
was visible within the plane of section and if cell profiles
exhibited distinctly delineated borders. For astrocytes the
hypertrophic cells have been identified as activated com-
pared to the thin cells presenting long processes.
Western blot analysis
Spinal cords were collected from each animal 3 and
7 days after formalin or saline injection, and they were
homogenized on ice in lysis buffer containing 1x PBS,
1% Nonidet-P40, 0.5% sodium deoxycholate, 0.1% SDS,
1 mM PMSF, 1 mM Na3VO4 and complete protease
inhibitor cocktail (Roche Diagnostics, Mannheim,
Germany). Tissue lysates were centrifuged at 16.200 g
for 15 min at 4°C, and the supernatants were used for
protein determination and stored at −80°C until use.
Western blot analysis were performed ex vivo on
spinal cord lysates of animals treated or not with forma-
lin (alone or with SA 2 mg/kg) for 3 and 7 days, to in-
vestigate the expression of inducible nitric oxide
Guida et al. Molecular Pain 2012, 8:60 Page 12 of 14
http://www.molecularpain.com/content/8/1/60synthase (iNOS). Protein lysates (70 μg) were separated
on SDS-polyacrylamide gels, and membranes were incu-
bated with anti-iNOS (BD Biosciences from Becton
Dickinson, Buccinasco, Italy) and anti-β-actin (Sigma,
Milan, Italy). Signals were visualized using ImageQuant
400 equipped with Quantity One Software 4.6.3 (GE
Healthcare, Milan, Italy).
Interleukin-10 level measurements
Interleukin-10 (IL-10) levels were measured on spinal
cord lysates obtained from animals treated or not with
formalin (alone or with SA 2 mg/kg) for 3 and 7 days as
reported above, using a commercial ELISA kit (Boster
Immunoleader from Tema Ricerca, Bologna, Italy)
according to the manufacturer’s instructions.
Chemicals
Salvinorin A (purity: 99% by HPLC) was isolated
from S. divinorum leaves. 3,4-Dichloro-N-methyl-N-[2-
(1-pyrrolidinyl)cyclohexyl]benzeneacetamide hydrochlor-




piperidin-1-ylpyrazole-3-carboxamide (AM251) and 6-
Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1 H-indol-3-yl]
(4-methoxyphenyl)methanone (AM630) were purchased
from Tocris Cookson (Northpoint, UK). All reagents for
western blot analysis were obtained from Sigma (Milan,
Italy), Bio-Rad Laboratories (Milan, Italy) and Microglass
Heim (Naples, Italy). All drugs used (i.e. SA, U-50488,
nor-BNI, AM251 and AM630) were dissolved in 0.5% v/v
DMSO in saline or aCFS, depending on the administration
route.
Data analysis
Behavioural and electrophysiological data were expressed
as mean ± S.E.M. (n= 6–8) and analyzed by using the
one-way analysis of variance (ANOVA) for repeated mea-
sures followed by the Student-Newman Keuls for multiple
comparisons to determine statistical significance between
different treated groups of mice. Immunohistochemical
data were expressed as mean ± S.E.M (n= 3) and analyzed
by using the one-way analysis of variance (ANOVA) for
repeated measures followed by Tukey post hoc. Biomole-
cular analysis and protein quantifications were expressed
as mean ± S.E.M (n= 3) and analyzed by t-test. P <0.05
was considered as significant.
Additional files
Additional file 1: Figure S1. Effect of vehicle or SA repeated treatment
(2 mg/kg, i.p.), alone or in presence of nor-BNI (20 mg/kg, i.p.), or AM251
(1 mg/kg, i.p.) on spinal microglial cells in mice receiving formalin intothe hind-paws. Iba-1 immunoreactivity (Iba-1-ir) is shown in the ipsilateral
dorsal horn 7 days after formalin (A-D). Quantitative analysis of
percentage of activated microglial cells on the total cell number in L4-L6
spinal cord sections is shown in “E”. Data are expressed as mean ± S.E.M
of 3 mice per group. * and ○ indicate statistically significant differences
vs veh/form and SA/form, respectively. (P <0.05, one-way ANOVA, Tukey
post hoc).
Additional file 2: Figure S2. Effect of vehicle or SA repeated treatment
(2 mg/kg, i.p.), alone or in presence of nor-BNI (20 mg/kg, i.p.), or AM251
(1 mg/kg, i.p.) on spinal astrocytes in mice receiving formalin into the
hind-paws. GFAP immunoreactivity (GFAP-ir) is shown in the ipsilateral
dorsal horn 7 days after formalin (A-D). Quantitative analysis of
percentage of activated astrocytes on the total cell number in L4-L6
spinal cord sections is shown in “E”. Data are expressed as mean ± S.E.M
of 3 mice per group. * and ○ indicate statistically significant differences
vs veh/form and SA/form, respectively. (P <0.05, one-way ANOVA, Tukey
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